WEBSITE BSE:544293 NSE: SURAKSHA Inc. Year: 2005 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:49
Suraksha Diagnostic Limited is a reputed provider of diagnostic and healthcare services. The company specializes in offering a wide range of diagnostic tests, including pathology, radiology, and imaging services. With a focus on precision, reliability, and patient care, Suraksha Diagnostic operates through a network of diagnostic centers equipped with state-of-the-art technology. Known for its commitment to quality and affordability, Suraksha Diagnostic has built a reputation for timely and accurate reporting, catering to both individual patie...Read More
Suraksha Diagnostic Limited is a reputed provider of diagnostic and healthcare services. The company specializes in offering a wide range of diagnostic tests, including pathology, radiology, and imaging services. With a focus on precision, reliability, and patient care, Suraksha Diagnostic operates through a network of diagnostic centers equipped with state-of-the-art technology. Known for its commitment to quality and affordability, Suraksha Diagnostic has built a reputation for timely and accurate reporting, catering to both individual patients and healthcare institutions. The company emphasizes innovation and continuous improvement, ensuring that its diagnostic solutions meet the highest industry standards. Through its patient-centric approach, Suraksha Diagnostic aims to enhance healthcare accessibility and contribute to the early detection and prevention of diseases. With a growing footprint, the company is positioned as a trusted name in the diagnostic sector, recognized for its excellence in service and commitment to community well-being. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹1471 Cr.
Stock P/E 47.5
P/B 6.2
Current Price ₹282.5
Book Value ₹ 45.6
Face Value 2
52W High ₹353.7
Dividend Yield 0%
52W Low ₹ 224.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 60 | 52 | 55 | 61 | 67 | 60 | 65 | 73 | 79 | 78 |
| Other Income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total Income | 61 | 53 | 56 | 62 | 68 | 60 | 66 | 73 | 80 | 78 |
| Total Expenditure | 39 | 37 | 36 | 40 | 44 | 41 | 46 | 49 | 55 | 55 |
| Operating Profit | 21 | 16 | 20 | 22 | 25 | 19 | 20 | 25 | 25 | 24 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 11 |
| Exceptional Income / Expenses | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 11 | 6 | 9 | 11 | 14 | 8 | 9 | 12 | 12 | 10 |
| Provision for Tax | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 |
| Profit After Tax | 8 | 5 | 6 | 8 | 10 | 6 | 7 | 9 | 9 | 7 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 8 | 5 | 7 | 8 | 10 | 6 | 7 | 9 | 9 | 8 |
| Adjusted Earnings Per Share | 121.9 | 67.4 | 1.9 | 1.5 | 2.4 | 1.2 | 1.4 | 1.8 | 1.7 | 1.4 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 70 | 99 | 157 | 140 | 223 | 190 | 219 | 252 | 295 |
| Other Income | 1 | 1 | 2 | 1 | 2 | 4 | 4 | 4 | 4 |
| Total Income | 71 | 100 | 159 | 141 | 225 | 194 | 222 | 256 | 297 |
| Total Expenditure | 53 | 77 | 123 | 117 | 175 | 146 | 148 | 170 | 205 |
| Operating Profit | 19 | 23 | 36 | 24 | 50 | 48 | 74 | 86 | 94 |
| Interest | 1 | 4 | 2 | 2 | 2 | 10 | 10 | 9 | 11 |
| Depreciation | 6 | 9 | 13 | 16 | 15 | 32 | 33 | 35 | 39 |
| Exceptional Income / Expenses | -0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Profit Before Tax | 12 | 10 | 21 | 6 | 33 | 7 | 31 | 41 | 43 |
| Provision for Tax | 4 | 5 | 6 | -0 | 9 | 1 | 8 | 10 | 11 |
| Profit After Tax | 8 | 5 | 15 | 6 | 24 | 6 | 23 | 31 | 32 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Profit After Adjustments | 8 | 5 | 15 | 6 | 24 | 7 | 24 | 32 | 33 |
| Adjusted Earnings Per Share | 109.6 | 79.7 | 220.5 | 93.3 | 344.2 | 94.4 | 342.4 | 6.1 | 6.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 4% | 10% | 0% |
| Operating Profit CAGR | 16% | 20% | 19% | 0% |
| PAT CAGR | 35% | 9% | 16% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -9% | NA% | NA% | NA% |
| ROE Average | 16% | 11% | 11% | 13% |
| ROCE Average | 25% | 19% | 17% | 17% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 49 | 55 | 120 | 126 | 150 | 156 | 179 | 211 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -1 |
| Borrowings | 19 | 29 | 8 | 10 | 12 | 8 | 5 | 3 |
| Other Non-Current Liabilities | 6 | 9 | 11 | 10 | 10 | 79 | 76 | 78 |
| Total Current Liabilities | 30 | 33 | 34 | 25 | 28 | 38 | 39 | 43 |
| Total Liabilities | 104 | 125 | 173 | 171 | 201 | 281 | 300 | 334 |
| Fixed Assets | 73 | 91 | 128 | 119 | 119 | 195 | 212 | 223 |
| Other Non-Current Assets | 6 | 8 | 17 | 25 | 60 | 18 | 16 | 63 |
| Total Current Assets | 25 | 26 | 28 | 27 | 22 | 68 | 72 | 47 |
| Total Assets | 104 | 125 | 173 | 171 | 201 | 281 | 300 | 334 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 18 | 12 | 3 | 4 | 3 | 3 | 2 | 3 |
| Cash Flow from Operating Activities | 20 | 13 | 31 | 24 | 42 | 44 | 60 | 63 |
| Cash Flow from Investing Activities | -42 | -26 | -20 | -28 | -44 | -21 | -35 | -40 |
| Cash Flow from Financing Activities | 17 | 10 | -10 | 3 | 1 | -24 | -25 | -24 |
| Net Cash Inflow / Outflow | -6 | -3 | 1 | -1 | -0 | -1 | 0 | -0 |
| Closing Cash & Cash Equivalent | 12 | 9 | 4 | 3 | 3 | 2 | 3 | 2 |
| # | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 109.61 | 79.69 | 220.48 | 93.26 | 344.2 | 94.43 | 342.4 | 6.11 |
| CEPS(Rs) | 190.66 | 212.72 | 403.02 | 320.97 | 562.91 | 546.9 | 807.6 | 12.73 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 695.52 | 775.22 | 1712.46 | 1805.72 | 2149.92 | 2236.19 | 2576.52 | 40.52 |
| Core EBITDA Margin(%) | 24.8 | 22.24 | 21.65 | 16.15 | 21.54 | 23.37 | 32.41 | 32.5 |
| EBIT Margin(%) | 18.59 | 14.2 | 14.63 | 5.91 | 15.81 | 8.58 | 18.77 | 20.02 |
| Pre Tax Margin(%) | 16.49 | 10.1 | 13.34 | 4.55 | 14.87 | 3.55 | 14.38 | 16.42 |
| PAT Margin (%) | 10.77 | 5.55 | 9.66 | 4.6 | 10.64 | 3.19 | 10.57 | 12.29 |
| Cash Profit Margin (%) | 18.74 | 14.81 | 17.66 | 15.82 | 17.4 | 19.85 | 25.48 | 26.29 |
| ROA(%) | 7.3 | 4.8 | 10.2 | 3.74 | 12.78 | 2.52 | 7.96 | 9.78 |
| ROE(%) | 15.76 | 10.84 | 17.73 | 5.3 | 17.4 | 4.01 | 13.93 | 15.93 |
| ROCE(%) | 16.8 | 16.12 | 20.19 | 6.04 | 22.65 | 9.62 | 22.94 | 24.92 |
| Receivable days | 13.93 | 13.32 | 12.22 | 15.63 | 11.09 | 11.76 | 11.31 | 16.42 |
| Inventory Days | 11.09 | 11.08 | 10.81 | 12.89 | 8.72 | 11.89 | 10.71 | 10.66 |
| Payable days | 487.36 | 290.78 | 196.29 | 181.56 | 80.01 | 185.93 | 190.4 | 173.33 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.19 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.36 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.34 | 0.41 | 0.1 | 0.15 | 0.11 | -0.17 | -0.17 | 5.27 |
| EV/Core EBITDA(x) | 1.3 | 1.76 | 0.45 | 0.86 | 0.49 | -0.68 | -0.51 | 15.49 |
| Net Sales Growth(%) | 0 | 41.2 | 58.87 | -11.11 | 59.42 | -14.81 | 15.03 | 15.26 |
| EBIT Growth(%) | 0 | 7.84 | 63.76 | -64.09 | 326.43 | -53.8 | 151.76 | 22.95 |
| PAT Growth(%) | 0 | -27.3 | 176.66 | -57.7 | 269.06 | -74.46 | 281.31 | 33.95 |
| EPS Growth(%) | 0 | -27.3 | 176.66 | -57.7 | 269.06 | -72.56 | 262.58 | -98.22 |
| Debt/Equity(x) | 0.58 | 0.77 | 0.1 | 0.13 | 0.13 | 0.09 | 0.05 | 0.03 |
| Current Ratio(x) | 0.84 | 0.8 | 0.83 | 1.1 | 0.78 | 1.77 | 1.84 | 1.1 |
| Quick Ratio(x) | 0.76 | 0.68 | 0.67 | 0.92 | 0.55 | 1.61 | 1.67 | 0.92 |
| Interest Cover(x) | 8.87 | 3.46 | 11.33 | 4.35 | 16.78 | 1.71 | 4.27 | 5.56 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2023 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 62.96 | 48.78 | 48.78 | 48.88 | 48.98 | 49 | 49.1 |
| FII | 0 | 15.39 | 14.46 | 13.95 | 13.72 | 13.46 | 13.46 |
| DII | 0 | 20.44 | 22.05 | 22.37 | 21.98 | 22.57 | 23.14 |
| Public | 37.04 | 15.39 | 14.7 | 14.8 | 15.31 | 14.98 | 14.31 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2023 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 0.04 | 2.54 | 2.54 | 2.55 | 2.55 | 2.55 | 2.56 |
| FII | 0 | 0.8 | 0.75 | 0.73 | 0.71 | 0.7 | 0.7 |
| DII | 0 | 1.06 | 1.15 | 1.17 | 1.14 | 1.18 | 1.2 |
| Public | 0.03 | 0.8 | 0.77 | 0.77 | 0.8 | 0.78 | 0.75 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.07 | 5.21 | 5.21 | 5.21 | 5.21 | 5.21 | 5.21 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
